Mohamed Abdel-Aal Ahmed, MD
Cardiovascular Disease · Buffalo, NYNPI 1164834776
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (48.7%), food and beverage and grants — rather than concentrated in one kind of arrangement. 25 manufacturers reported payments, led by Edwards Lifesciences at 35.1% of the total. Reporting peaked in 2023 at $9,703 and has fallen 56.9% since, to $4,182 in 2025.
Across 183 payments — averaging $92.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Edwards Lifesciences$6K
- Medtronic$5K
- Abbott$2K
- Heartflow, Inc.$2K
- Abiomed$991
- Boston Scientific$643
- plus $1K from 19 others
What the payments were for
- Grants$3,00018%
- Travel & lodging$8,27149%
- Food & beverage$5,54333%
- Education$1641%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Edwards Lifesciences | 40 | $5,955 |
| Medtronic | 16 | $4,942 |
| Abbott | 8 | $1,664 |
| Heartflow, Inc. | 10 | $1,658 |
| Abiomed | 32 | $991 |
| Boston Scientific | 45 | $643 |
| Philips North America LLC | 9 | $386 |
| Cardiovascular Systems Inc. | 1 | $148 |
| Amgen | 2 | $103 |
| Chiesi USA, Inc. | 1 | $79 |
| Pfizer | 2 | $47 |
| Cathworks, Inc. | 1 | $45 |
| Phathom Pharmaceuticals, Inc. | 2 | $45 |
| Inari Medical, Inc. | 2 | $42 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $34 |
| Novo Nordisk | 1 | $24 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $23 |
| Inspire Medical Systems, Inc. | 1 | $22 |
| Novartis | 1 | $21 |
| Dexcom, Inc. | 1 | $21 |
| W. L. Gore & Associates, Inc. | 1 | $20 |
| GSK | 1 | $20 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Merck | 1 | $15 |
| AbbVie | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$4,041
- Edwards SAPIEN 3 Transcatheter Heart Valve$3,176
- PASCAL$1,522
- FFRct$1,367
- AMPLATZER AMULET$1,271
- OPTIS$200
- ONYX FRONTIER$164
- GENERAL VASCULAR ACCESS$162
- Diamondback Coronary$148
- (9520) IGT Devices Undivided$113
- NA$110
How this compares
$16,978 in reported general payments places this provider in the 85th percentile of 2,302 cardiovascular disease providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 11 | $280 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Buffalo
- Saurabh MalhotraBuffalo$438K
- Roger HajjarNew York$5.2M
- Szilard VorosStony Brook$3.7M
- Gregg StoneNew York$2M
- Augustin DelagoAlbany$1.8M
- Philippe GenereuxNew York$1.3M
- Adam RosenbluthNew York$1.1M
- Luigi di BiaseBronx$978K
- Vijay IyerAmherst$855K
- Megha PrasadNew York$813K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.